Wisconsin Alumni Research Foundation

University of Washington

John M Denu

Kirk Tanner

Adam L Garske

Andrew M Scharenberg

Weiping Tang

The present disclosure provides compounds according to Formula I and pharmaceutically acceptable salts thereof, as well as compositions including such compounds and a pharmaceutically acceptable carrier or excipient. Further provided are methods of inactivating SIRT6 with compounds of Formula I as well as compounds of Formula III, W—R—Y—R, as described herein. In addition, the present technology provides methods of treatment using such compounds to lower LDL levels, lower triglyceride levels, and/or increase glucose tolerance in a subject, and/or to inhibit proliferation of ovarian, colorectal, hepatocellular, non-small cell lung, glioblastoma, osteosarcoma, pancreatic, and skin cancer cells, and/or inhibit liver and/or kidney fibrosis, and/or promote corneal epithelial wound healing.

Sirtuin 6 protein deacylase (SIRT6) activators

A method for determining protein binding specificity using a screen of a peptide library is provided. The method can be used to determine binding specificity for human NAD-dependent deacetylase SIRT1, and to identify the most efficiently deacetylated peptide sequences. The method can be also used to screen a combinatorial H4 histone N-terminal tail peptide library to examine the binding preferences of a &#x3b1;-phos (S1) H4 antibody toward all known possible H4 histone modification states.

Methods for determining protein binding specificity using peptide libraries

Compositions and methods are disclosed which are effective for modulating glucose homeostasis, calcium ion flux and cell death in target cells.

Compositions and methods for modulating calcium flux, glucose homeostasis and apoptosis

Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging.

Growing community of inventors

McFarland, WI, United States of America

John M Denu